AI Brain Magnetic Resonance Imaging (MRI) Lesion Detection Market Report 2026

The AI brain MRI lesion detection market size has grown exponentially in recent years. It will grow from $1.0 billion in 2025 to $1.22 billion in 2026 at a compound annual growth rate (CAGR) of 22.2%. The growth in the historic period can be attributed to increasing use of MRI in neurology, growing adoption of digital radiology, rising incidence of brain tumors and stroke, expanding hospital investments in imaging systems, increasing need for early disease diagnosis.

The AI brain MRI lesion detection market size is expected to see exponential growth in the next few years. It will grow to $2.69 billion in 2030 at a compound annual growth rate (CAGR) of 21.9%. The growth in the forecast period can be attributed to growing demand for AI-enabled diagnostics, rising government support for healthcare AI, expanding adoption of cloud medical imaging, increasing integration of AI with PACS systems, rising investment in tele-radiology solutions. Major trends in the forecast period include growing demand for AI-enabled diagnostics, rising government support for healthcare AI, expanding adoption of cloud medical imaging, increasing integration of AI with PACS systems, rising investment in tele-radiology solutions.

The increasing prevalence of neurological disorders is expected to propel the growth of the artificial intelligence (AI) brain MRI lesion detection market going forward. Neurological disorders are medical conditions that affect the brain, spinal cord, and nerves, disrupting normal nervous system function and leading to impairments in movement, cognition, sensation, behavior, or overall bodily control. The rising prevalence of neurological disorders is driven by unhealthy lifestyle habits, including poor diet, physical inactivity, smoking, excessive alcohol consumption, and chronic stress. AI brain MRI lesion detection supports patients with neurological disorders by enabling faster and more accurate identification of brain abnormalities, facilitating early diagnosis, personalized treatment planning, and improved overall patient outcomes. For instance, in April 2024, according to the National Institutes of Health (NIH), a US-based government’s premier biomedical research agency, an estimated 6.9 million Americans aged 65 and older are currently living with Alzheimer’s dementia, and this figure is projected to nearly double to 13.8 million by 2060. Therefore, the increasing prevalence of neurological disorders drives the artificial intelligence (AI) brain MRI lesion detection market.

Leading companies operating in the artificial intelligence (AI) brain MRI lesion detection market are focusing on developing innovative solutions, such as AI-powered contrast enhancement systems, to improve early detection of subtle brain abnormalities and enhance diagnostic accuracy. AI-powered contrast enhancement systems use advanced algorithms to increase lesion visibility on contrast-enhanced MRI scans, improving lesion-to-brain and contrast-to-noise ratios without modifying standard acquisition protocols. For instance, in October 2024, Bracco Diagnostics, a US-based medical imaging company, and Subtle Medical, a US-based AI healthcare company, launched AiMIFY software. This AI-based brain MRI enhancement tool amplifies contrast enhancement up to two times compared with standard gadolinium-based imaging and improves the visibility of lesions while maintaining existing scanning workflows. This launch represents a significant technological advancement by integrating AI with conventional imaging, bridging advanced computational analysis with clinical radiology practice. It offers a scalable, efficient solution for enhancing diagnostic confidence and early lesion detection in neurological imaging.

In September 2025, GE HealthCare, a US-based key player in medical imaging systems, AI-enabled diagnostics, and healthcare solutions, acquired icometrix for an undisclosed amount. Through this acquisition, GE HealthCare aims to strengthen its neurology portfolio and integrate icometrix’s AI-powered brain imaging analysis (icobrain platform) into its MRI systems to support detection and quantification of neurological abnormalities, including Alzheimer’s-related imaging biomarkers. icometrix is a Belgium-based provider of AI-driven brain imaging analysis solutions that assist in the detection and monitoring of neurological disorders via MRI.

Major companies operating in the artificial intelligence (AI) brain magnetic resonance imaging (mri) lesion detection market are Aidoc Medical Ltd., RapidAI Inc., Annalise.ai Pty Ltd., Quibim S.L., Olea Medical Imaging SAS, DeepTek.ai Inc., Image Analysis Group Ltd., Subtle Medical Inc., Gleamer SAS, Raidium Ltd., Invicro LLC, CorTechs.ai Inc., Omniscient Neurotechnology Inc., NeoSoma Inc., Oxipit Ltd., Cerebriu Inc., BrainReader ApS, MedImaging AI Solutions Ltd., NeuroVision Imaging Inc., NeuroQuant Analytics Inc.

North America was the largest region in the AI brain MRI lesion detection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI) brain magnetic resonance imaging (mri) lesion detection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence (AI) brain magnetic resonance imaging (mri) lesion detection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs are influencing the ai brain mri lesion detection market by raising costs of imported mri hardware components, gpus, edge computing devices, and high-performance imaging processors. hospitals and diagnostic imaging centers in north america and europe are most affected due to dependence on imported imaging infrastructure, while asia-pacific faces higher system integration costs. these tariffs are increasing capital expenditure and slowing system upgrades. at the same time, they are supporting localized software development, regional ai model training initiatives, and domestic innovation in medical imaging analytics.

Artificial intelligence (AI) brain magnetic resonance imaging (MRI) lesion detection involves the use of AI algorithms to automatically identify abnormal lesions in brain MRI scans. This technology enhances diagnostic accuracy by analyzing complex imaging patterns that may be challenging for clinicians to detect consistently. It facilitates faster clinical decision-making and supports early detection of neurological diseases.

The key components of artificial intelligence (AI) brain MRI lesion detection include software, hardware, and services. Software consists of AI-driven platforms and algorithms that analyze brain MRI scans to automatically detect, classify, and interpret abnormalities. Lesion categories include tumors, vascular lesions, demyelinating lesions, traumatic lesions, and others. Imaging modalities include 2D MRI, 3D MRI, and others. Applications include tumor detection, multiple sclerosis evaluation, stroke assessment, traumatic brain injury, and more, with primary users being hospitals, diagnostic imaging centers, research institutions, and others.

The artificial intelligence (AI) brain magnetic resonance imaging (MRI) lesion detection market consists of revenues earned by entities by providing services such as algorithm development, model training, cloud-based image analysis, diagnostic reporting, and data annotation. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence (AI) brain magnetic resonance imaging (MRI) lesion detection market also includes sales of MRI scanners, imaging hardware modules, GPU servers, and data storage devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.